‘Stop Prescribing Hydroxychloroquine for COVID-19’

Translate to Spanish or other 102 languages!

Florida Atlantic University/Getty Images
In 2021, in the U.S. alone, there have been more than 560,000 prescriptions of hydroxychloroquine. Last year, the 890,000 prescriptions were nine-fold greater than the previous years.

Mega Doctor News

- Advertisement -

By Florida Atlantic University

Newswise – In 2021, in the United States alone, there have been more than 560,000 prescriptions of hydroxychloroquine for the prevention, post-exposure and treatment of COVID-19. Since the onset in February 2020, the U.S. has been the epicenter of the pandemic and remains the world leader in cases and deaths. Last year, the 890,000 prescriptions for hydroxychloroquine were nine-fold greater than the previous years, leading to major shortages for the approved indications of autoimmune disease predominantly in younger women.     

In a commentary published in The American Journal of Medicine, researchers from Florida Atlantic University’s Schmidt College of Medicine and collaborators review the recent major randomized, double-blind placebo-controlled trials and present an updated meta-analysis of hydroxychloroquine in post-exposure prophylaxis as well as in hospitalized patients. Last year, these same researchers issued a plea for a moratorium on prescription of hydroxychloroquine in prevention or treatment pending the outcome of ongoing randomized trials. 

- Advertisement -

“The updated randomized evidence provides even stronger support for the halt on prescribing hydroxychloroquine in the prevention or treatment of COVID-19,” said Charles H. Hennekens, M.D., Dr.PH, senior author, the first Sir Richard Doll professor and senior academic advisor in FAU’s Schmidt College of Medicine.

The authors say that in addition to a lack of significant benefit, the new randomized evidence shows some suggestion of harm. They explain that the prior reassuring safety profile of hydroxychloroquine is applicable to patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle-age women, whose risks of fatal heart outcomes due to hydroxychloroquine are reassuringly very low.

In contrast, the risks of hydroxychloroquine for patients with COVID-19 are significantly higher because fatal cardiovascular complications due to these drugs are so much higher in older patients and those with existing heart disease or its risk factors, both of whom are more predominant in men.  “Premature and avoidable deaths will continue to occur if people take hydroxychloroquine and avoid the public health strategies of proven benefit, which include vaccinations and masking,” added Hennekens. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

New Book Gives Families Language to Discuss Epilepsy

Each November, National Epilepsy Awareness Month invites people to learn how to recognize and respond to a seizure. For many families, the harder conversation happens at home: how do you explain epilepsy to a child? According to the CDC, an estimated 456,000 children in the United States had active epilepsy in 2022. McAllen author Cariño Sandoval wrote Daniel’s Big, Bright Heart with these families in mind. It launches today on Amazon in paperback and ebook.

DHR Health Sets RGV Patient Safety Standard with Another ‘A’ Grade

DHR Health in Edinburg has once again earned an “A” hospital safety grade from The Leapfrog Group, an independent national nonprofit watchdog focused on patient safety. 

United States and Mexico Lose Measles Elimination Status Amid Continued Outbreaks

The United States, Mexico and Bolivia have lost their measles elimination status after the highly contagious virus circulated continuously for more than 12 months, the Pan American Health Organization (PAHO) announced November 17, 2026.

Keep Thanksgiving Stress-Free with STHS Food Safety Tips

The holiday season is a time for gathering with loved ones, celebrating family traditions and enjoying home-cooked meals. 
- Advertisement -